From Self-sufficiency
Jump to: navigation, search
Systematic (IUPAC) name
3-butylamino-4-phenoxy-5-sulfamoyl-benzoic acid
Clinical data
  • AU: B3
  • US: C (Risk not ruled out)
Routes of
Legal status
Legal status
  • AU: S4 (Prescription only)
  • UK: POM (Prescription only)
  • US: ℞-only
Pharmacokinetic data
Bioavailability almost complete (~80%)
Protein binding 97%
Metabolism hepatic
Biological half-life ~0.8 hours
Excretion renal
CAS Number 28395-03-1
ATC code C03CA02 (WHO)
PubChem CID 2471
DrugBank APRD00294
ChemSpider 2377
Chemical data
Formula C17H20N2O5S
Molar mass 364.417 g/mol[[Script error: No such module "String".]]
Script error: No such module "collapsible list".
Script error: No such module "TemplatePar".Expression error: Unexpected < operator.

Bumetanide (Trade name Bumex) is a loop diuretic of the sulfamyl category to treat heart failure. It is often used in patients in whom high doses of furosemide are ineffective. It is marketed by Hoffmann-La Roche with the brand name Bumex. The main difference between the two substances is in bioavailability and pharmacodynamic potency. Furosemide is incompletely absorbed in the intestine (60%), and there is substantial inter- and intraindividual differences in bioavailability (range 10-90%). Bumetanide is completely absorbed (80%), and the absorption is not altered when it is taken with food. It is said to be a more predictable diuretic, meaning that the predictable absorption is reflected in a more predictable effect.[1]

Bumetanide is 40 times more potent than furosemide (for patients with normal renal function).[1]

On October 24, 2008, ESPN reported a number of NFL players were being suspended under the steroid policy as a result of taking Bumetanide. The drug is often used for weight loss, but also to mask other drugs or steroids by helping to dilute the contents of the user's urine (which is manifested through its actions on the Loop of Henle -- see loop diuretic), yielding a lower concentration of filtered substances which may then go undetected.

Bumetanide was an undisclosed active ingredient in the over the counter weight loss supplement StarCaps. StarCaps was pulled off the market after the presence of the undisclosed ingredient was discovered by the Food and Drug Administration.


Cite error: Invalid <references> tag; parameter "group" is allowed only.

Use <references />, or <references group="..." />


External links


it:Bumetanide pt:Bumetanida

  1. 1.0 1.1 Brunton, Laurence et al. Goodman & Gilman's The Pharmacological Basis of THERAPEUTICS. 11th ed. 2006. 749-753